<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03670082</url>
  </required_header>
  <id_info>
    <org_study_id>17482A</org_study_id>
    <nct_id>NCT03670082</nct_id>
  </id_info>
  <brief_title>Study With Lu AF35700 in Healthy Men and Women in Fasting and Fed State</brief_title>
  <official_title>Interventional, Open-label, Two-way Crossover, Single-dose Study Investigating the Absolute Bioavailability and Food Effect on the Pharmacokinetics of Lu AF35700 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the extent to which Lu AF35700 enters the
      bloodstream following pill intake and the influence of food on the uptake in healthy men and
      women
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each subject will receive a single oral dose of Lu AF35700 on Day 1 in each Period. Subjects
      in Group 1 will be in fasting condition in Period I and in a fed condition in Period II.
      Subjects in Group 2 will be in fed condition in Period I and in fasting condition in Period
      II.

      For Group 1, period 1 only, a single intravenous micro-dose of Lu AF35700 will be given 4
      hours after oral dosing.

      All subjects will be confined to the clinic from one day prior to the first dosing until Day
      6 (120 hours post dose) for each dosing period. Periods I and II will be separated by a
      period of 6 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 5, 2018</start_date>
  <completion_date type="Actual">January 13, 2019</completion_date>
  <primary_completion_date type="Actual">December 21, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute bioavailability Fabs</measure>
    <time_frame>0 to 120 hours</time_frame>
    <description>Fabs= 100*(AUC0-72h, po*Div) / (AUC0-72h, iv*Dpo) (where D is the dose)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-inf: area under the Lu AF35700 plasma concentration-time curve from zero to 72 hours</measure>
    <time_frame>0 to 120 hours</time_frame>
    <description>Area under the plasma concentration-time curve from zero to 72 hours for Lu AF35700</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax: maximum observed plasma concentration</measure>
    <time_frame>0 to 120 hours</time_frame>
    <description>Maximum observed plasma concentration of Lu AF35700</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax: time at maximum observed plasma concentration</measure>
    <time_frame>0 to 120 hours</time_frame>
    <description>Time at which maximum observed plasma concentration of Lu AF35700 occurred</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Group 1: Fasting condition in Period I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be in fasting condition in Period I and in a fed condition in Period II.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Fed condition in Period I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be in fed condition in Period I and in fasting condition in Period II.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lu AF35700</intervention_name>
    <description>20 mg Lu AF35700 single oral dose</description>
    <arm_group_label>Group 1: Fasting condition in Period I</arm_group_label>
    <arm_group_label>Group 2: Fed condition in Period I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lu AF35700 iv</intervention_name>
    <description>100 μg [14C]-Lu AF35700 (4.7 μCi/174 kBq) single intravenous micro-dose</description>
    <arm_group_label>Group 1: Fasting condition in Period I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy men and women aged ≥18 and ≤55 years

          -  Body Mass Index (BMI) of ≥18.5 and ≤30 kg/m2

          -  Subject must be in good general health as assessed using medical history, clinical
             laboratory tests, and physical examination

        Exclusion Criteria:

          -  The subject must not be of childbearing potential (if a woman) or should use
             contraception, be surgically sterilized or not be sexually active (both sexes). Women
             must not be pregnant or lactating

          -  The subject must not be a CYP2D6 or a CYP2C19 poor metabolizer

        Other inclusion and exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials@Lundbeck.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>September 12, 2018</study_first_submitted>
  <study_first_submitted_qc>September 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2018</study_first_posted>
  <last_update_submitted>October 31, 2019</last_update_submitted>
  <last_update_submitted_qc>October 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

